Business Context and Reporting Period
Company: Atossa Therapeutics, Inc. (ATOS)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Business Overview: Atossa is a clinical-stage biopharmaceutical company focused on developing proprietary medicines for breast cancer and other breast conditions. Its lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, currently in Phase 2 trials for breast cancer prevention and treatment. The company has no commercial revenue and relies on capital raises to fund operations.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(25,504) | $(30,094) |
| Operating Expenses | $27,621 | $31,377 |
| Research & Development (R&D) | $14,117 | $17,334 |
| General & Administrative (G&A) | $13,504 | $14,043 |
| Interest Income | $4,050 | $4,343 |
| Cash and Cash Equivalents (Year End) | $71,084 | $88,460 |
| Working Capital | $69,490 | $86,983 |
| Accumulated Deficit | $(211,792) | $(186,288) |
Debt and Liquidity: The company has no long-term debt. As of December 31, 2024, it held approximately $71.1 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least the next 12 months. The company entered into an Open Market Sale Agreement in November 2024 to sell up to $100 million of common stock, though no shares were sold under this agreement in 2024.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $4.6 million (15%) from 2023 to 2024, primarily driven by reduced operating expenses.
- R&D Expense Decrease: R&D expenses fell by $3.2 million (19%), largely due to decreased spending on clinical trials and a reduction in non-cash stock-based compensation.
- G&A Expense Decrease: G&A expenses declined by $0.5 million (4%). While professional fees increased by $1.8 million (due to legal fees for patent defense and S-3 filing), this was offset by a $1.9 million decrease in compensation expenses.
- Impairment Charges: The company recorded a $1.7 million impairment charge in 2024 related to its investment in Dynamic Cell Therapies, Inc. (DCT), which ceased operations. This compares to a $3.0 million impairment in 2023.
- Capital Activity: In 2024, the company received $3.7 million from warrant exercises, issuing 3.67 million shares. In 2023, the company repurchased $1.5 million of its own stock.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Clinical Progress
- EVANGELINE Trial: A Phase 2 neoadjuvant study for premenopausal women. The protocol was revised in January 2025 to focus on a 40 mg dose based on safety and efficacy data from the 80 mg cohort. Part 2 is expected to initiate in the first half of 2025.
- Karisma-(Z)-endoxifen: Phase 2 data showed significant reduction in mammographic breast density (17.3% at 1 mg, 23.5% at 2 mg) with a favorable safety profile at the lower dose.
- I-SPY 2 EOP: Preliminary data showed (Z)-endoxifen met primary endpoints with 95% of patients receiving >75% of planned treatment and significant reduction in Ki-67 biomarkers. A new arm combining (Z)-endoxifen with abemaciclib is ongoing.
- Metastatic Indication: In March 2025, the company announced a strategic decision to pursue a metastatic breast cancer indication, potentially offering a more efficient regulatory pathway.
Risks and Contingencies
- Nasdaq Compliance: On February 21, 2025, the company received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to the stock price failing to maintain a $1.00 minimum closing bid price for 30 consecutive days. The company has until August 20, 2025, to regain compliance.
- Patent Litigation: On January 29, 2025, the PTAB issued a final decision finding all claims of U.S. Patent No. 11,572,334 (related to methods for making and using endoxifen) unpatentable. The company decided not to appeal due to cost and time.
- Going Concern: The company has a history of operating losses and no revenue. Continued operations depend on raising additional capital, which may not be available on acceptable terms.
- Australian Tax Liability: The company recorded a $1.5 million liability related to uncertainty regarding the sustainability of its Australian R&D tax rebate position under audit.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $71.1 million cash balance against projected burn rates, especially given the lack of revenue and upcoming clinical trial costs.
- Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid requirement by August 20, 2025, to avoid delisting.
- Patent Portfolio: Assess the impact of the PTAB decision invalidating a key patent on the company's intellectual property protection and competitive moat.
- Clinical Trial Protocols: Review the revised EVANGELINE trial protocol (40 mg dose) and the timeline for Part 2 initiation to gauge near-term data readouts.
- Capital Raising: Track the utilization of the $100 million Open Market Sale Agreement and any future equity offerings that may cause dilution.